{"id":"NCT01606007","sponsor":"AstraZeneca","briefTitle":"Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes","officialTitle":"A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Add-On Therapy With Saxagliptin and Dapagliflozin Added to Metformin Compared to Add-On Therapy With Saxagliptin in Combination With Metformin or Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07","primaryCompletion":"2014-01","completion":"2014-01","firstPosted":"2012-05-25","resultsPosted":"2015-10-20","lastUpdate":"2017-05-15"},"enrollment":1282,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"Saxagliptin","otherNames":["Onglyza"]},{"type":"DRUG","name":"Metformin XR","otherNames":["Glucophage XR"]},{"type":"DRUG","name":"Dapagliflozin","otherNames":["BMS-512148"]},{"type":"DRUG","name":"Placebo matching with Dapagliflozin","otherNames":[]},{"type":"DRUG","name":"Placebo matching with Saxagliptin","otherNames":[]}],"arms":[{"label":"Arm 1: Saxagliptin+Metformin XR+Placebo","type":"ACTIVE_COMPARATOR"},{"label":"Arm 2: Dapagliflozin+Metformin XR+Placebo","type":"ACTIVE_COMPARATOR"},{"label":"Arm 3: Saxagliptin+Dapagliflozin+Metformin XR","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to learn if a combination of BMS-477118 (Saxagliptin) and BMS -512148 (Dapagliflozin) added to Metformin can improve (decrease) Glycosylated Hemoglobin (Hemoglobin A1c) in patients with type 2 diabetes after 24 weeks of treatment. The safety of this treatment will also be studied.","primaryOutcome":{"measure":"Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24","timeFrame":"Baseline (Week 0) and at Week 24","effectByArm":[{"arm":"Arm 1: Saxagliptin+Metformin XR+Placebo","deltaMin":-0.88,"sd":null},{"arm":"Arm 2: Dapagliflozin+Metformin XR+Placebo","deltaMin":-1.2,"sd":null},{"arm":"Arm 3: Saxagliptin+Dapagliflozin+Metformin XR","deltaMin":-1.47,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"0.0166"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":139,"countries":["United States","Canada","Mexico","Poland","Puerto Rico","Romania","South Africa","South Korea"]},"refs":{"pmids":["25352655","31364269","30304106"],"seeAlso":["http://www.bms.com/studyconnect/Pages/home.aspx","http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3665&filename=CV_181169_Protocol_Redacted.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3665&filename=CV181169_Synopsis.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":176},"commonTop":[]}}